Improved Glycemic Control Using Intrinsic Factor Bound to a Vitamin B12 Conjugate of a Glucagon-Like Peptide-1 Receptor Agonist

David S. Hermelin (Inventor), Jonathan D. Bortz (Inventor), Robert Doyle (Inventor)

Research output: Patent

Abstract

The present invention provides compositions and methods for lowering blood glucose. More specifically, the present invention provides compositions comprising a complex comprising IF and B12 conjugated to a peptide comprising a GLP-1 agonist. Advantageously, the composition may be delivered subcutaneously.
Original languageEnglish (US)
StatePublished - Nov 20 2017

Fingerprint

Intrinsic Factor
Glucagon-Like Peptide 1
Vitamin B 12
Blood Glucose
Peptides
Glucagon-Like Peptide-1 Receptor

Cite this

@misc{f1529089c1394073a4bb0f8d503c0f4a,
title = "Improved Glycemic Control Using Intrinsic Factor Bound to a Vitamin B12 Conjugate of a Glucagon-Like Peptide-1 Receptor Agonist",
abstract = "The present invention provides compositions and methods for lowering blood glucose. More specifically, the present invention provides compositions comprising a complex comprising IF and B12 conjugated to a peptide comprising a GLP-1 agonist. Advantageously, the composition may be delivered subcutaneously.",
author = "Hermelin, {David S.} and Bortz, {Jonathan D.} and Robert Doyle",
year = "2017",
month = "11",
day = "20",
language = "English (US)",
type = "Patent",

}

TY - PAT

T1 - Improved Glycemic Control Using Intrinsic Factor Bound to a Vitamin B12 Conjugate of a Glucagon-Like Peptide-1 Receptor Agonist

AU - Hermelin, David S.

AU - Bortz, Jonathan D.

AU - Doyle, Robert

PY - 2017/11/20

Y1 - 2017/11/20

N2 - The present invention provides compositions and methods for lowering blood glucose. More specifically, the present invention provides compositions comprising a complex comprising IF and B12 conjugated to a peptide comprising a GLP-1 agonist. Advantageously, the composition may be delivered subcutaneously.

AB - The present invention provides compositions and methods for lowering blood glucose. More specifically, the present invention provides compositions comprising a complex comprising IF and B12 conjugated to a peptide comprising a GLP-1 agonist. Advantageously, the composition may be delivered subcutaneously.

M3 - Patent

ER -